Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Capital Expenditures (2021 - 2025)

Biote has reported Capital Expenditures over the past 5 years, most recently at $4.5 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $4.5 million for Q4 2025, up 517.73% from a year ago — trailing twelve months through Dec 2025 was $5.0 million (up 9930.0% YoY), and the annual figure for FY2025 was $5.0 million, up 9930.0%.
  • Capital Expenditures for Q4 2025 was $4.5 million at Biote, up from $191000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for BTMD hit a ceiling of $4.5 million in Q4 2025 and a floor of -$1.3 million in Q2 2025.
  • Median Capital Expenditures over the past 5 years was $138000.0 (2024), compared with a mean of $343555.6.
  • Biggest five-year swings in Capital Expenditures: plummeted 3280.0% in 2023 and later soared 1817.65% in 2025.
  • Biote's Capital Expenditures stood at -$538000.0 in 2021, then skyrocketed by 100.93% to $5000.0 in 2022, then plummeted by 3280.0% to -$159000.0 in 2023, then tumbled by 570.44% to -$1.1 million in 2024, then skyrocketed by 517.73% to $4.5 million in 2025.
  • The last three reported values for Capital Expenditures were $4.5 million (Q4 2025), $191000.0 (Q3 2025), and -$1.3 million (Q2 2025) per Business Quant data.